|
gptkbp:instanceOf
|
gptkb:anticoagulant
direct thrombin inhibitor
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvalYear
|
2000
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
B01AE06
|
|
gptkbp:brand
|
gptkb:Angiomax
Angiox
|
|
gptkbp:CASNumber
|
128270-60-0
|
|
gptkbp:contraindication
|
active bleeding
severe uncontrolled hypertension
hypersensitivity to bivalirudin
|
|
gptkbp:discoveredBy
|
gptkb:The_Medicines_Company
|
|
gptkbp:eliminationHalfLife
|
25 minutes
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C98H138N24O33
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bivalirudin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to thrombin
inhibits fibrin formation
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:origin
|
derived from hirudin
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:product
|
synthetic 20-amino acid peptide
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
bleeding
back pain
|
|
gptkbp:usedFor
|
gptkb:heparin-induced_thrombocytopenia
unstable angina
percutaneous coronary intervention
|
|
gptkbp:bfsParent
|
gptkb:Angiomax
|
|
gptkbp:bfsLayer
|
7
|